PANORAMA ACTUEL DES MEDICAMENTS HYPOLIPEMIANTSHELLER F; HARVENGT C.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 209-219; BIBL. 3 P.Article

LES MEDICAMENTS HYPOLIPIDEMIANTSBONTE JP; BERTHELOT P.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 243-262; BIBL. 2 P.Article

PLAFIBRIDE TOLERANCE TRIAL AT INCREASING DOSES IN HEALTY VOLUNTEERSDALMAU J; VICENS B; ZAPATERO J et al.1981; ARZNEIM.-FORSCH.; ISSN 0004-4172; DEU; DA. 1981; VOL. 31; NO 10; PP. 1840-1844; ABS. GER; BIBL. 8 REF.Article

THE UNCOMMON PHARMACOLOGY OF CHENODEOXYCHOLIC ACID: THE FIRST REGULATOR OF BILIARY CHOLESTEROL LEVELS IN MANHOFMANN AF.1980; EUR. J. CLIN. INVEST.; ISSN 0014-2972; GBR; DA. 1980; VOL. 257-258; BIBL. 13 REF.Article

SUPPRESSION OF ACUTE-PHASE SYNTHESIS OF FIBRINOGEN BY A HYPOLIPIDERNIC DRUG (CLOFIBRATE)PICKART L.1981; INT. J. TISSUE REACT.; ISSN 0250-0868; CHE; DA. 1981; VOL. 3; NO 2; PP. 65-72; BIBL. 22 REF.Article

HYPOLIPIDEMIC ACTIVITY OF PHTHALIMIDE DERIVATIVES. I: N-SUBSTITUTED PHTHALIMIDE DERIVATIVESCHAPMAN JM JR; COCOLAS GH; HALL IH et al.1979; J. MEDICIN. CHEM.; USA; DA. 1979; VOL. 22; NO 11; PP. 1399-1402; BIBL. 40 REF.Article

NEW HYPOLIPIDEMIC DRUGSBENCZE WL.1978; ADV. EXPER. MED. BIOL.; USA; DA. 1978; VOL. 109; PP. 77-95; BIBL. 61 REF.Conference Paper

LE "CLOFIBRATE" ET DERIVES.VETEL JM; ADVENIER C.1977; GAZ. MED. FR.; FR.; DA. 1977; VOL. 84; NO 9; PP. 935-938 (3P.)Article

CLOFIBRAT-VERBOT-WAS NUN. = CLOFIBRATE UNTERDIT: QU'EN EST-IL MAINTENANTSCHWARTZKOPFF W.1979; MUENCH. MED. WSCHR.; DEU; DA. 1979; VOL. 121; NO 15; PP. 529-533; ABS. ENG; BIBL. 27 REF.Article

ASPECTS BIOCHIMIQUES ET EXPERIMENTAUX DE LA PHARMACOLOGIE DES MEDICAMENTS HYPOLIPIDEMIANTSJACOTOT B.1979; SEM. HOP.; FRA; DA. 1979; VOL. 55; NO 41-42; PP. 1947-1955; ABS. ENG; BIBL. 28 REF.Article

LE MODE D'ACTION DES MEDICAMENTS HYPOLIPEMIANTS.LOEPER J; LOEPER J et al.ROUFFY J; LOEPER J; LOEPER J et al.1976; BULL. ACAD. NATION. MED.; FR.; DA. 1976; VOL. 160; NO 5; PP. 434-438Article

NACH DEM CLOFIBRAT-VERBOT VERFUEGBARE LIPIDSENKER. KLINISCH-PHARMAKOLOGISCHE SICHTUNG = SELECTION DES HYPOLIPEMIANTS APRES LE VERDICT DU CLOFIBRATE. POINTS DE VUE CLINIQUES ET PHARMACOLOGIQUESMERTZ DP.1979; FORTSCHR. D. MED.; DEU; DA. 1979; VOL. 97; NO 15; PP. 695-698; ABS. ENG; BIBL. 24 REF.Article

HYPOCHOLESTEROLEMIC EFFECTS OF CHITOSAN IN CHOLESTEROL-FED RATSSUGANO M; FUJIKAWA T; HITATSUJI Y et al.1978; NUTRIT. REP. INTERNATION.; USA; DA. 1978; VOL. 18; NO 5; PP. 531-537; BIBL. 19 REF.Article

TOLERANCE HEPATIQUE DU PROCETOFENEROSSI A.1978; NOUV. PRESSE MED.; FRA; DA. 1978; VOL. 7; NO 35; PP. 3153Article

A REAPPRAISAL OF THE MECHANISMS OF HYPOCHOLESTEROLEMIC ACTION OF THERAPEUTIC AGENTSSODHI HS; KUDCHODKAR BJ; CLIFFORD C et al.1978; ADV. EXPER. MED. BIOL.; USA; DA. 1978; VOL. 109; PP. 331-345; BIBL. 33 REF.Conference Paper

LANGZEITTHERAPIE MIT ETOFIBRAT = TRAITEMENT A LONG TERME AVEC L'ETOFIBRATEKAFFARNIK H; SCHNEIDER J; SCHUBOTZ R et al.1980; MUENCH. MED. WSCHR.; DEU; DA. 1980; VOL. 122; NO 3; PP. 95-98; ABS. ENG; BIBL. 25 REF.Article

ETUDE DE L'ACTIVITE HYPOLIPIDEMIQUE DES DERIVES DES ISOFLAVONESKAZAKOV AL.1979; KHIMIKO-FARM. ZH.; SUN; DA. 1979; VOL. 13; NO 1; PP. 58-60; BIBL. 7 REF.Article

BEEINTRAECHTIGT CHOLESTYRAMIN DIE BIOLOGISCHE VERFUEGBARKEIT VON PREDNISOLON. = LA CHOLESTYRAMINE NUIT-ELLE A LA DISPONIBILITE BIOLOGIQUE DE LA PREDNISOLONE.AUDETAT V; PAUMGARTNER G; BIRCHER J et al.1977; SCHWEIZ. MED. WSCHR.; SCHWEIZ.; DA. 1977; VOL. 107; NO 15; PP. 527-528; ABS. ANGL.; BIBL. 10 REF.Article

PROBENECID-CLOFIBRATE INTERACTIONVEENENDAAL JR; BROOKS PM; MEFFIN PJ et al.1981; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1981; VOL. 29; NO 3; PP. 351-358; BIBL. 18 REF.Article

TOXICOLOGICAL STUDIES OF PLAFIBRIDE. I: ACUTE TOXICITY AND ITS DETERMINATION AFTER SEVERAL ADMINISTRATIONS OF PLAFIBRIDEZAPATERO J; SANFELIU C; BRUSEGHINI L et al.1981; ARZNEIM.-FORSCH.; ISSN 0004-4172; DEU; DA. 1981; VOL. 31; NO 10; PP. 1816-1819; ABS. GER; BIBL. 3 REF.Article

HYPOLIPAEMIC ACTIVITY OF 1-(THEOPHYLLIN-7-YL)-ETHYL-2- (2-(P-CHLORPHENOXY)-2-METHYLPROPIONATE) (ETOFYLLINE CLOFIBRATE) AND ITS ANALOGUES IN NORMOLIPAEMIC RATSGINOCCHIO AV; METZ G.1980; ARZNEIM.-FORSCH.; ISSN 0004-4172; DEU; DA. 1980; VOL. 30; 11B; PP. 2032-2034; ABS. GER; BIBL. 8 REF.Article

SELECTIVE EFFECTS OF CLOFIBRATE ON ALKALINE PHOSPHATASE ISOENZYMES IN SERUMWHITAKER KB; COSTA D; MOSS DW et al.1979; CLIN. CHIM. ACTA; NLD; DA. 1979; VOL. 94; NO 2; PP. 191-196; BIBL. 20 REF.Article

PHARMACOLOGIE DES HYPOLIPEMIANTSALLAIN P; CAILLEUX A; RICHARD H et al.1979; CONCOURS MED.; FRA; DA. 1979; VOL. 101; NO 21; PP. 3559-3576; BIBL. 32 REF.Article

HYPOLIPEMIC ACTIVITY OF CLOFIBRATE-RELATED COMPOUNDS. II. COMMUNICATION.METZ G; SPECKER M.1977; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1977; VOL. 27; NO 7; PP. 1421-1424; ABS. ALLEM.; BIBL. 7 REF.Article

BIOAVAILABILITY AND PHARMACOKINETICS IN MAN IN ACIPIMOX: A NEW ANTILIPOLYTIC AND HYPOLIPENIC AGENTMUSATTI L; MAGGI E; MORO E et al.1981; J. INT. MED. RES.; ISSN 0300-0605; GBR; DA. 1981; VOL. 9; NO 5; PP. 381-386; BIBL. 7 REF.Article